Nadolol NDC 70518-4662

NDC codes

FDA NDC Directory

Product NDC (as listed)70518-4662Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70518-4662Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70518-4662-0	70518466200	50 POUCH in 1 BOX (70518-4662-0) / 1 TABLET in 1 POUCH (70518-4662-1)Marketed from May 18, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Nadolol
Generic name (nonproprietary): nadolol
Active ingredients: Nadolol — 40 mg/1
Dosage form: Tablet
Route: Oral
Labeler: REMEDYREPACK INC.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 201893
Marketing start: May 18, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Adrenergic beta-Antagonists (Mechanism)
Identifiers: Product ID 70518-4662_52197684-ee04-b2c5-e063-6294a90afc94SPL ID 52197684-ee04-b2c5-e063-6294a90afc94SPL set ID 8a224f90-24a5-411e-ac26-6496a1930f3aRxCUI 198007UNII FEN504330V
Pharmacologic class: beta-Adrenergic Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470518466200 followed by a unit qualifier and the quantity

Package 70518-4662-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 18, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets. Control of high blood pressure should be part of comprehensive cardiov…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 201893

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 201893
Product	Strength	Form · route	Labeler	Product NDC
Nadolol	Nadolol 40 mg/1	TabletOral	BluePoint Laboratories	68001-691
Nadolol	Nadolol 20 mg/1	TabletOral	BluePoint Laboratories	68001-690
Nadolol	Nadolol 80 mg/1	TabletOral	BluePoint Laboratories	68001-692
Nadolol	Nadolol 40 mg/1	TabletOral	Aurobindo Pharma Limited	59651-251
Nadolol	Nadolol 80 mg/1	TabletOral	Aurobindo Pharma Limited	59651-252
Nadolol	Nadolol 20 mg/1	TabletOral	Aurobindo Pharma Limited	59651-589